Latest news with #CatherineBrownstein
Yahoo
6 days ago
- Business
- Yahoo
Dream Impact Trust Announces Voting Results of Annual Meeting of Unitholders
TORONTO, June 03, 2025--(BUSINESS WIRE)--DREAM IMPACT TRUST (TSX: (the "Trust") announced that, at its annual meeting of unitholders (the "Meeting") held today, all of the nominees for election as trustees of the Trust (the "Trustees") referred to in its management information circular for the Meeting (the "Circular") were elected. Votes cast on this matter were as follows: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Amar Bhalla 7,754,302 98.71 101,589 1.29 Dr. Catherine Brownstein 7,696,342 97.97 159,549 2.03 Robert Goodall 7,752,220 98.68 103,671 1.32 Jennifer Lee Koss 7,698,437 98.00 157,454 2.00 Karine MacIndoe 7,746,987 98.61 108,904 1.39 At the Meeting, PricewaterhouseCoopers LLP was appointed as the auditor of the Trust, Dream Impact Master LP and the Trust's subsidiaries for the ensuing year, and the Trustees were authorized to fix the remuneration of the auditor. Votes cast on this matter were as follows: Votes For % Votes For Votes Withheld % Votes Withheld PricewaterhouseCoopers LLP 7,813,038 99.09 72,079 0.91 About Dream Impact Trust Dream Impact is an open-ended trust dedicated to impact investing. Dream Impact's underlying portfolio is comprised of exceptional real estate assets reported under two operating segments: development and recurring income, that would not be otherwise available in a public and fully transparent vehicle, managed by an experienced team with a successful track record in these areas. The objectives of Dream Impact are to create positive and lasting impacts for our stakeholders through our three impact verticals: environmental sustainability and resilience, attainable and affordable housing, and inclusive communities, while generating attractive returns for investors. For more information, please visit: View source version on Contacts Meaghan PelosoChief Financial Officer(416) 365-6322mpeloso@ Kim LefeverDirector, Investor Relations(416) 365-6339klefever@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 days ago
- Business
- Business Wire
Dream Impact Trust Announces Voting Results of Annual Meeting of Unitholders
TORONTO--(BUSINESS WIRE)-- DREAM IMPACT TRUST (TSX: (the ' Trust ') announced that, at its annual meeting of unitholders (the ' Meeting ') held today, all of the nominees for election as trustees of the Trust (the ' Trustees ') referred to in its management information circular for the Meeting (the ' Circular ') were elected. Votes cast on this matter were as follows: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Amar Bhalla 7,754,302 98.71 101,589 1.29 Dr. Catherine Brownstein 7,696,342 97.97 159,549 2.03 Robert Goodall 7,752,220 98.68 103,671 1.32 Jennifer Lee Koss 7,698,437 98.00 157,454 2.00 Karine MacIndoe 7,746,987 98.61 108,904 1.39 Expand At the Meeting, PricewaterhouseCoopers LLP was appointed as the auditor of the Trust, Dream Impact Master LP and the Trust's subsidiaries for the ensuing year, and the Trustees were authorized to fix the remuneration of the auditor. Votes cast on this matter were as follows: About Dream Impact Trust Dream Impact is an open-ended trust dedicated to impact investing. Dream Impact's underlying portfolio is comprised of exceptional real estate assets reported under two operating segments: development and recurring income, that would not be otherwise available in a public and fully transparent vehicle, managed by an experienced team with a successful track record in these areas. The objectives of Dream Impact are to create positive and lasting impacts for our stakeholders through our three impact verticals: environmental sustainability and resilience, attainable and affordable housing, and inclusive communities, while generating attractive returns for investors. For more information, please visit:
Yahoo
21-02-2025
- Business
- Yahoo
The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
PROVIDENCE, R.I., Feb. 21, 2025 /CNW/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program. The program is focused on making structural variation detection more accessible to human genomics researchers by providing Nabsys' OhmX platform on consignment to selected labs. Fifteen (15) RAMP UP grants were awarded in total, with participants currently progressing through various stages of the consignment agreement process. Upon completion, participants will use the OhmX platform to analyze structural variants (SVs) for various applications, including rare disease, cancer, and cell and gene therapy. Some specific applications include the analysis of repeat expansions, orthogonal confirmation of long-read sequencing calls, determining detection sensitivity for rare SVs, and enhanced cytogenetic profiling. "I look forward to establishing electronic genome mapping as a core service for the Boston Children's Hospital research community. The technology seems promising for high-resolution analysis of structural variants" said Dr. Catherine Brownstein, a RAMP UP recipient at Boston Children's Hospital and Director of the Genomics Core. The institutions participating in the program include: Ann & Robert H. Lurie Children's Hospital of Chicago (Dr. Miriam Bornhorst) Be Biopharma (Dr. Huei-Mei Chen) Boston Children's Hospital (Dr. Catherine Brownstein) Brigham and Women's Hospital (Dr. Phillip Michaels) Drexel University (Dr. Ming Xiao) Labcorp (Dr. Adam C. Smith) Seattle Children's Hospital (Dr. Cate Paschal and Dr. Anica Wandler) Stanford University (Dr. Alexander E. Urban) Texas A&M University (Dr. Kenneth S. Ramos) The Jackson Laboratory (Dr. Mark Adams, Dr. Charles Lee, Dr. Feyza Yilmaz) The Translational and Advanced Medicine Center (Dr. Kevin P. Clancy) University of Florida (Dr. Eric Wang) Yale University (Dr. Ryan B. Jensen) "Collaborations through the OhmX RAMP UP Grant Program represent our commitment to advancing genomic research by empowering the world's leading institutions with cutting-edge technology," said Craig Kerkove, President & CEO, HTA. "We are proud to support the groundbreaking work of these researchers, who are at the forefront of understanding and addressing the complexities of genetic diseases and cancer." "In awarding OhmX instruments to these prestigious laboratories, we have made a significant step forward in our mission to democratize access to genomic tools," noted Nabsys CEO, Dr. Barrett Bready. "This collaboration between Nabsys and HTA exemplifies our shared vision of powering innovation to drive transformative advancements in genomics and healthcare." OhmX's electronic nanochannel-based platform allows researchers to conduct targeted and whole-genome structural-variant analysis, leading to a better understanding of disease mechanisms, gene disruption, and complex genomic regions. This improved understanding empowers precision medicine with the potential to create more effective and personalized treatments, while also overcoming the cost and complexity barriers that are typically associated with SV analysis. About Nabsys 2.0, LLCThe Nabsys 2.0, LLC ("Nabsys") mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis. For more information, visit About Hitachi High-Tech America, High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide, with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit Contact InformationElise Benson Director of MarketingNabsysbenson@ View original content to download multimedia: SOURCE Nabsys View original content to download multimedia: Sign in to access your portfolio
Associated Press
21-02-2025
- Business
- Associated Press
The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research
PROVIDENCE, R.I., Feb. 21, 2025 /CNW/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the awardees of their OhmX Rapid Application to Market Penetration User Partnership, or OhmX RAMP UP, Grant Program. The program is focused on making structural variation detection more accessible to human genomics researchers by providing Nabsys' OhmX platform on consignment to selected labs. Fifteen (15) RAMP UP grants were awarded in total, with participants currently progressing through various stages of the consignment agreement process. Upon completion, participants will use the OhmX platform to analyze structural variants (SVs) for various applications, including rare disease, cancer, and cell and gene therapy. Some specific applications include the analysis of repeat expansions, orthogonal confirmation of long-read sequencing calls, determining detection sensitivity for rare SVs, and enhanced cytogenetic profiling. 'I look forward to establishing electronic genome mapping as a core service for the Boston Children's Hospital research community. The technology seems promising for high-resolution analysis of structural variants' said Dr. Catherine Brownstein, a RAMP UP recipient at Boston Children's Hospital and Director of the Genomics Core. The institutions participating in the program include: Ann & Robert H. Lurie Children's Hospital of Chicago (Dr. Miriam Bornhorst) Be Biopharma (Dr. Huei-Mei Chen) Boston Children's Hospital (Dr. Catherine Brownstein) Brigham and Women's Hospital (Dr. Phillip Michaels) Drexel University (Dr. Ming Xiao) Labcorp (Dr. Adam C. Smith) Seattle Children's Hospital (Dr. Cate Paschal and Dr. Anica Wandler) Stanford University (Dr. Alexander E. Urban) Texas A&M University (Dr. Kenneth S. Ramos) The Jackson Laboratory (Dr. Mark Adams, Dr. Charles Lee, Dr. Feyza Yilmaz) The Translational and Advanced Medicine Center (Dr. Kevin P. Clancy) University of Florida (Dr. Eric Wang) Yale University (Dr. Ryan B. Jensen) 'Collaborations through the OhmX RAMP UP Grant Program represent our commitment to advancing genomic research by empowering the world's leading institutions with cutting-edge technology,' said Craig Kerkove, President & CEO, HTA. 'We are proud to support the groundbreaking work of these researchers, who are at the forefront of understanding and addressing the complexities of genetic diseases and cancer.' 'In awarding OhmX instruments to these prestigious laboratories, we have made a significant step forward in our mission to democratize access to genomic tools,' noted Nabsys CEO, Dr. Barrett Bready. 'This collaboration between Nabsys and HTA exemplifies our shared vision of powering innovation to drive transformative advancements in genomics and healthcare.' OhmX's electronic nanochannel-based platform allows researchers to conduct targeted and whole-genome structural-variant analysis, leading to a better understanding of disease mechanisms, gene disruption, and complex genomic regions. This improved understanding empowers precision medicine with the potential to create more effective and personalized treatments, while also overcoming the cost and complexity barriers that are typically associated with SV analysis. About Nabsys 2.0, LLC The Nabsys 2.0, LLC ('Nabsys') mission is to advance the understanding of disease, increase diagnostic yield, and improve patient outcomes by enabling routine, accurate, cost-effective analysis of genomic structural variation. Located in Providence, RI, Nabsys employs a growing interdisciplinary group of dedicated scientists, engineers, and other professionals committed to the advancement of genomic analysis. For more information, visit About Hitachi High-Tech America, Inc. Hitachi High-Tech America, Inc. (HTA) is a privately-owned global affiliate company that operates within the Hitachi Group companies. HTA sells and services semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products, as well as industrial equipment, and electronic and industrial materials. HTA is dedicated to successful and profitable collaboration with leading companies worldwide, with a direction towards providing customers with superior quality products and services at fair and competitive prices. For more information, please visit
